Search Results
Aug 13, 2026, 04:32 ET atNorth's Camilla O'Leary Announced as Co-Chair of the Infrastructure Masons' iMWomen Initiative
https://news.cision.com/atnorth/r/atnorth-s-camilla-o-leary-announced-as-co-chair-of-the-infrastructure-masons--imwomen-initiative,c4382848The following files are available for download:
More news about: atNorth
Aug 13, 2026, 04:30 ET atNorth's Camilla O'Leary Announced as Co-Chair of the Infrastructure Masons' iMWomen Initiative
https://news.cision.com/atnorth/r/atnorth-s-camilla-o-leary-announced-as-co-chair-of-the-infrastructure-masons--imwomen-initiative,c4382848The following files are available for download:
More news about: atNorth
Aug 13, 2026, 02:34 ET Quantinuum publie ses résultats du deuxième trimestre 2026
résultats du deuxième trimestre témoignent d'une mise en œuvre rigoureuse de notre stratégie. Nous avons réalisé des avancées décisives en matière de R&D, afin de faire progresser notre feuille de route technologique et de renforcer notre position concurrentielle, nous avons consolidé notre chaîne d'approvisionnement
More news about: Quantinuum
Aug 13, 2026, 02:27 ET Hexaware and upGrad Enterprise Expand Collaboration for Global Enterprise AI Programs
decisions with less dependence on specialist technology teams."Enterprise AI programs are increasingly constrained by execution capacity," said R. Srikrishna, CEO & Executive Director, Hexaware. "Clients need architecture, engineering, and business teams aligned to a common delivery agenda—a
More news about: Hexaware Technologies Limited
Aug 13, 2026, 02:26 ET Sivers Semiconductors Announces $3.4M Program With SemiNex for Next-Generation InP Light Sources Used to Power AI Data Centers
https://news.cision.com/sivers-semiconductors/r/sivers-semiconductors-announces--3-4m-program-with-seminex-for-next-generation-inp-light-sources-use,c4382694
More news about: Sivers Semiconductors
Aug 13, 2026, 02:00 ET Global AI & Cybersecurity Capture-the-Flag Competition Opens with ₹10 Lakhs+ Prize Pool
by people, and led by our purpose, we partner with our clients from design to operation. Our digital solutions, proprietary platforms, engineering, R&D, products, and innovation ecosystem turn core challenges into impactful, disruptive business outcomes. With deep industry knowledge and a future-ready
More news about: UST
Aug 13, 2026, 01:48 ET Skanska signs an additional contract for a data center in Virginia, USA, worth USD 238M, about SEK 2.2 billion
https://news.cision.com/skanska/r/skanska-signs-an-additional-contract-for-a-data-center-in-virginia--usa--worth-usd-238m--about-sek-2,c4382685The following files are available for download:
More news about: Skanska
Aug 13, 2026, 01:39 ET Lumo Homes plc's Half-Year Financial Report 1 January-30 June 2026
https://news.cision.com/lumo-homes-plc/r/lumo-homes-plc-s-half-year-financial-report-1-january-30-june-2026,c4382734The following files are available for download:
More news about: Lumo Homes plc
Aug 13, 2026, 01:26 ET Strong Share Price Appreciation Drives Revaluation of Social Tax Liability in Q2 2026
https://news.cision.com/sivers-semiconductors/r/strong-share-price-appreciation-drives-revaluation-of-social-tax-liability-in-q2-2026,c4382722
More news about: Sivers Semiconductors
Aug 12, 2026, 21:00 ET ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations.Key pipeline assets include: ziresovir (AK0529), the first direct-acting antiviral
More news about: Shanghai Ark Biopharmaceutical Co., Ltd.
Aug 12, 2026, 21:00 ET ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations.Key pipeline assets include: ziresovir (AK0529), the first direct-acting antiviral
More news about: Shanghai Ark Biopharmaceutical Co., Ltd.
Aug 12, 2026, 18:29 ET MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 57,2 BILLION FOR THE PAST 12 MONTHS
content:https://www.prnewswire.co.uk/news-releases/minerva-foods-reports-record-net-revenue-of-r-57-2-billion-for-the-past-12-months-302850206.html
More news about: Minerva Foods
Aug 12, 2026, 18:26 ET MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 57,2 BILLION FOR THE PAST 12 MONTHS
content:https://www.prnewswire.com/news-releases/minerva-foods-reports-record-net-revenue-of-r-57-2-billion-for-the-past-12-months-302850203.htmlSOURCE
More news about: Minerva Foods
Aug 12, 2026, 18:09 ET /C O R R E C T I O N -- Green Evolution Technologies/
and agricultural technology company commercializing InteliGel™, a patented physicochemical hydrogel delivery platform. Built on 55+ years of family R&D and Industrialization, GET's manufacturing process produces industrial-scale output at a capital cost that is structurally inaccessible to conventional
More news about: Green Evolution Technologies
Aug 12, 2026, 18:02 ET /C O R R E C T I O N -- First Responders Children's Foundation/
More news about: First Responders Children's Foundation
Aug 12, 2026, 17:30 ET Alarum Technologies, Ltd. (ALAR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announces that investors with losses related to Alarum Technologies, Ltd. (ALAR) have opportunity to lead the securities fraud
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Aug 12, 2026, 17:00 ET Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
creation.Financial Results for the Quarter Ended June 30, 2026Research and Development (R&D) expenses: R&D expenses for the quarter ended June 30, 2026, were $1.4 million compared to $1.4 million for the comparable period in 2025.General
More news about: Azitra, Inc.
Aug 12, 2026, 16:05 ET Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Quarter 2026 Financial InformationThe cash and investments balance was $17.1 million as of June 30, 2026.Combined R&D and SG&A expenses for the second quarter of 2026 totaled $3.9 million compared to $3.7 million for the second quarter of 2025. Excluding non-cash
More news about: Talphera, Inc.
Aug 12, 2026, 16:05 ET INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
were approximately $18.3 million.Second Quarter 2026 Financial Results Research and Development (R&D) Expenses: R&D expenses for the three months ended June 30, 2026 decreased to $10.8 million from $14.5 million for the same period in 2025. The decrease
More news about: INOVIO Pharmaceuticals, Inc.
Aug 12, 2026, 16:05 ET Cyngn Reports 2026 2nd Quarter Financial Results
million or 29% from $10.8 million for the six months ended June 30, 2025. This increase was due to a $2.0 million increase in research and development (R&D), primarily due to personnel costs driven by the change in accounting estimate related to capitalized software. In addition, the company experienced
More news about: Cyngn
Aug 12, 2026, 16:05 ET SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
expenses for the second quarter of 2026 were $3.5 million, compared to $3.3 million in the prior-year period, reflecting restructuring-related costs; R&D spending expected to decline in future periods.Selling, general and administrative expenses for the second quarter of 2026 were $6.5 million,
More news about: Sera Prognostics, Inc.
Aug 12, 2026, 15:00 ET Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
their trust and support."About Aurisco Aurisco Pharmaceutical Co., Ltd. (SSE: 605116) serves global markets since 1998. With 6 R&D centers, 4 manufacturing sites and sales offices in USA, Portugal, India and Brazil, the company focuses on complex products. With 100+ patents filled
More news about: Aurisco Pharmaceutical
Aug 12, 2026, 15:00 ET Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
their trust and support."About Aurisco Aurisco Pharmaceutical Co., Ltd. (SSE: 605116) serves global markets since 1998. With 6 R&D centers, 4 manufacturing sites and sales offices in USA, Portugal, India and Brazil, the company focuses on complex products. With 100+ patents filled
More news about: Aurisco Pharmaceutical